Michael Quadrini, MD
Nephrology · Huntsville, ALNPI 1831258698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $273,309 of the $322,919 with a category attached, or 84.6%. 29 manufacturers reported payments, led by Amgen at 57.9% of the total. Reporting peaked in 2022 at $100,579 and has fallen 98.4% since, to $1,654 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 747 payments — averaging $432.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$187K
- Bayer$105K
- Otsuka America Pharmaceutical, Inc.$16K
- GSK$6K
- Vifor Pharma, Inc.$4K
- AstraZeneca$1K
- plus $4K from 23 others
Across 94 payments — averaging $11,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$856K
- Bayer$210K
- Biogen$24K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
What the payments were for
- Consulting fees$19,9006%
- Speaking & faculty fees$273,30985%
- Travel & lodging$17,7525%
- Food & beverage$11,8504%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 240 | $187,075 |
| Bayer | 142 | $104,825 |
| Otsuka America Pharmaceutical, Inc. | 64 | $15,944 |
| GSK | 32 | $6,434 |
| Vifor Pharma, Inc. | 54 | $4,094 |
| AstraZeneca(2 entities) | 66 | $1,005 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $750 |
| Novartis | 19 | $494 |
| OPKO Pharmaceuticals, LLC | 33 | $410 |
| Calliditas Therapeutics US Inc. | 16 | $362 |
| Travere Therapeutics, Inc. | 17 | $247 |
| Boehringer Ingelheim | 11 | $236 |
| Aurinia Pharma U.S., Inc. | 8 | $192 |
| Akebia Therapeutics Inc | 7 | $167 |
| Novo Nordisk | 5 | $112 |
| Lilly USA, LLC | 5 | $98 |
| Fresenius USA Marketing, Inc. | 5 | $84 |
| Ultragenyx Pharmaceutical Inc. | 3 | $69 |
| Apellis Pharmaceuticals, Inc. | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $33 |
| AMAG Pharmaceuticals, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Cormedix Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$322,919 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 28 | $76,723 |
| KerendiaFinerenone | 63 | $61,582 |
| VeltassaPatiromer Calcium Sorbitex | 43 | $38,845 |
| Lanthanum Carbonate | 18 | $33,206 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $19,512 |
| Sevelamer Carbonate | 72 | $10,253 |
| Nifedipine ErNifedipine | 84 | $4,031 |
| Calcium Acetate | 13 | $1,764 |
| Midodrine Hcl | 19 | $1,274 |
| Cinacalcet Hcl | 14 | $1,168 |
| Calcitriol | 49 | $1,156 |
| Potassium Citrate ErPotassium Citrate | 21 | $1,000 |
| Hydralazine Hcl | 39 | $986 |
| Potassium Chloride | 47 | $785 |
| Mycophenolate Mofetil | 16 | $749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $84 | $76,72328 claims |
| BayerKerendia | $104,825 | $61,58263 claims |
| AstraZenecaLokelma | $1,005 | $19,51227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 nephrology providers in Alabama.
Other nephrology in Huntsville
- James SmelserHuntsville$20K
- Carlo CastilloHuntsville$7K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Roger CoomerHuntsville$6K
- David BainsHuntsville$5K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.